CD8 T cell populations in anti-HIV gag cytotoxic T cell activity.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

CD8 T cell populations in anti-HIV gag cytotoxic T cell activity.

Int Conf AIDS. 1992 Jul 19-24;8(2):A34 (abstract no. PoA 2188). Unique Identifier : AIDSLINE ICA8/92400483
Watret KC; Froebel KS; Bird AG; Dept. Medicine, Royal Infirmary, Edinburgh, Scotland.

Abstract: OBJECTIVE: To characterise, phenotypically, the CD8+ cell population involved in anti-HIV class-I MHC-restricted cytotoxic T cell (CTL) activity in HIV +ve individuals. METHODS: CTL activity was studied in 15 HIV +ve patients; 12/15 patients in CDC stage III and 3/15 patients in CDC stage IV. A 4 hour 51Chromium release assay was used. Autologous EBV transformed B cell lines infected with a vaccinia-HIVgag construct were incubated in vitro with cultured patient cells. Lymphocyte surface markers were determined on both whole blood and cultured lymphocytes, using a panel of monoclonal antibodies; HLA-DR, CD45RA (marker on immature T cells), CD29 and CD45RO (markers on mature T cells) CD57 (NK cells), and S6F1 (cytotoxic T cells). Cells were analysed by flow cytometry. RESULTS: Anti-HIVgag CTL activity was found in 8/12 of the CDC stage III patients and 0/3 of CDC stage IV group. The 7/15 patients with no detectable CTL activity had significantly reduced CD4 counts (P less than 0.005) when compared to the CTL +ve group. All patients had increased levels of CD8 cells co-expressing HLA-DR, CD45RO, CD29, S6F1 and CD57 when compared to controls. Analysis of in vitro cultured cells showed that CTL activity was found only in patients cells in which a significant increase in %CD8 CD45RO+ and HLA-DR+ cells (P less than 0.005) had occurred. CONCLUSION: Anti-HIVgag CTL activity is lost in the later stages of disease, and correlates with loss in CD4 cells. The loss of CTL activity was associated with an inability of CD8 CD45RO+ and HLA-DR+ cells to expand in vitro.

Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Antigens, CD/ANALYSIS Antigens, CD8/*ANALYSIS Comparative Study Cytotoxicity, Immunologic Gene Products, gag/*IMMUNOLOGY Human HIV Seropositivity/*IMMUNOLOGY HIV-1/*IMMUNOLOGY HLA-DR Antigens/ANALYSIS Lymphocyte Transformation T-Lymphocyte Subsets/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/*IMMUNOLOGY ABSTRACT
921230
M92C4864

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .